Capstone Therapeutics Corp. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2012; filed August 10, 2012. The filing identifies the registrant as Capstone Therapeutics Corp., a development-stage biotechnology company, although the request metadata refers to Capstone Holding Corp.
Business Context and Reporting Period
The company develops peptide-based therapies for underserved medical conditions and has no revenue-producing operations following the 2003 sale of its bone-device business. During 2012, Capstone materially curtailed internal operations, ceased clinical development of AZX100 in dermal scarring, and discontinued TP508 development. TP508-related intellectual property was returned to the University of Texas Medical Branch in March 2012.
As of June 30, 2012, the company had reduced its workforce to two employees and was focused on completing regulatory and statutory obligations, seeking strategic or licensing transactions for AZX100, and maintaining public-company compliance.
Financial Results and Position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| General and administrative expense | $0.393 million in 2012 vs. $0.797 million in 2011 | $0.817 million vs. $1.962 million |
| Research and development expense | $0.403 million vs. $1.376 million | $0.959 million vs. $3.458 million |
| Total operating expenses | $0.796 million vs. $2.173 million | $1.776 million vs. $5.420 million |
| Net loss | $0.712 million vs. $2.169 million | $1.688 million vs. $5.406 million |
| Loss per share | $0.02 vs. $0.05 | $0.04 vs. $0.13 |
| Cash flow from operating activities | $(1.124) million in the first six months, vs. $(4.760) million in 2011 |
The filing does not report operating revenue. Interest and other income, net was $88,000 in the first six months of 2012, including an $80,000 gain on the sale of laboratory equipment.
Cash and cash equivalents were $12.824 million at June 30, 2012, compared with $13.778 million at December 31, 2011. Total assets were $13.058 million, total current liabilities were $93,000, and stockholders’ equity was $12.965 million. The filing reports no debt balance. Accumulated deficit was $176.205 million at June 30, 2012, including approximately $148 million of losses incurred during the development-stage period.
Material Changes Versus Prior Comparable Period
- Second-quarter net loss declined approximately 67% year over year, and six-month net loss declined approximately 69%, primarily because of workforce reductions and the wind-down of internal operations.
- Six-month operating cash burn improved to $1.124 million from $4.760 million.
- Research and development expense decreased approximately 72% for the quarter and 72% for the six-month period.
- General and administrative expense decreased approximately 51% for the quarter and 58% for the six-month period.
- Cash declined $954,000 during the first six months, partly offset by $170,000 of proceeds from the sale of laboratory equipment.
- Shares outstanding increased to 40,885,411 at June 30, 2012 from 40,775,411 at December 31, 2011.
Outlook, Unusual Items, Risks, and Contingencies
On August 3, 2012, after the reporting period, Capstone formed LipimetiX Development LLC with LipimetiX LLC to develop AEM-28 and analogs. Capstone agreed to contribute $6 million, comprising $1 million for a 60% voting common ownership interest and $5 million in preferred units. Approximately $3.3 million was to be funded initially, with approximately $2.7 million held in escrow pending FDA allowance of an IND. The joint venture’s initial plan targets Phase 1a and Phase 1b/2a trials over approximately 27 months for severe refractory hypercholesterolemia and homozygous familial hypercholesterolemia.
Management estimated 2012 cash expenditures of approximately $2.5 million for reduced operations, excluding the $6 million joint-venture contribution and potentially significant qui tam litigation costs. Management expected cash and short-term investments at June 30, 2012 to fund projected working-capital needs for the following year, but stated that substantial additional capital would be required for full clinical development and regulatory approval.
The company is defending a qui tam action alleging improper promotion and billing practices involving the former bone-device business. The government declined to intervene; no trial date had been set and discovery had not begun. Management believed a material loss was not reasonably possible based on available information, but acknowledged that an adverse outcome could exceed the company’s financial resources and materially impair liquidity and operations.
The filing states that the company’s prior going-concern uncertainty related to corporate strategy was alleviated by formation of the AEM-28 joint venture. The joint venture investment nevertheless represents a substantial portion of available cash, and there is no assurance of FDA orphan-drug designation, favorable trial results, a liquidity event, or recovery of the investment.
Investor Verification Items
- Confirm the identity discrepancy between the requested company name, Capstone Holding Corp., and the registrant named in the filing, Capstone Therapeutics Corp.
- Verify the August 3, 2012 joint-venture agreements, ownership structure, $6 million funding commitment, escrow conditions, and consolidation treatment.
- Assess post-period cash levels after the joint-venture contribution and whether the projected cash runway remains adequate.
- Review the status, potential damages, insurance coverage, and liquidity implications of the qui tam litigation.
- Confirm whether AZX100 partnering efforts produced any subsequent transaction or whether further development was discontinued.
- Evaluate the clinical, regulatory, financing, and execution risks associated with AEM-28, including FDA IND and orphan-drug milestones.